Large, Chronic Doses of Erythropoietin Cause Thrombocytopenia in Mice

• Published in: Blood Vol. 80; no. 2; pp. 352 - 358
• Main Authors: McDonald, T.P., Clift, Rose E., Cottrell, Marilyn B.
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 15-07-1992; The Americain Society of Hematology
• Subjects: Animals; Biological and medical sciences; Blood Platelets - drug effects; Blood Platelets - immunology; Blood Platelets - metabolism; Blood Volume - drug effects; Bone Marrow - pathology; Erythrocyte Count; Erythropoietin - toxicity; Hematocrit; Hematologic and hematopoietic diseases; Immune Sera - administration & dosage; Male; Medical sciences; Megakaryocytes - drug effects; Megakaryocytes - pathology; Mice; Mice, Inbred C3H; Platelet Count - drug effects; Platelet diseases and coagulopathies; Recombinant Proteins - toxicity; Splenectomy; Sulfates - blood; Sulfur Radioisotopes; Thrombocytopenia - blood; Thrombocytopenia - chemically induced; Thrombocytopenia - pathology; Thrombocytopenia; Vertebrata; Experimental disease; Platelet; Mammalia; Erythropoietin; Mouse; Animal; Rodentia; Hemopathy
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V80.2.352.352

Both large, acute doses of erythropoietin (EPO) and short-term hypoxia increase platelet counts in mice, but long-term hypoxia causes thrombocytopenia. Therefore, we tested the hypothesis that EPO injected in large, chronic doses (a total of 80 U of EPO over a 7-day period) might cause thrombocytopenia. EPO caused increased red blood cell (RBC) production, ie, increased hematocrits, RBC counts, mean cell volume (MCV), and reticulocyte counts (from P less than .05 to P less than .0005), and decreased thrombocytopoiesis, ie, decreased platelet counts, percent 35S incorporation into platelets, and total circulating platelet counts (TCPC) (P less than .0005). Femoral marrow megakaryocyte size was unchanged, but megakaryocyte number was significantly (P less than .005) reduced in mice treated with EPO. EPO-injected mice had increased spleen volumes (P less than .0005), but blood volumes (BV) were unchanged. In EPO-treated, splenectomized mice, RBC production was also increased (P less than .05 to P less than .0005) and platelet counts, TCPC, and percent 35S incorporation into platelets were decreased (P less than .05), but BV was not altered. Therefore, the decrease in platelet counts observed in EPO-treated mice was not due to increased BV or to an enlarged spleen. In other experiments, mice were rendered acutely thrombocytopenic to increase thrombocytopoiesis, and platelet and RBC production rates were determined. In mice with elevated thrombocytopoiesis, RBC counts, hematocrits, percent 59Fe RBC incorporation values, and MCV were decreased (P less than .05 to P less than .0005). Because 59Fe RBC incorporation and MCV were not elevated, the decrease in RBC counts and hematocrits does not appear to be due to bleeding. Therefore, we show that large, chronic doses of EPO increase erythropoiesis and decrease thrombocytopoiesis. Conversely, acute thrombocytopenia causes increased thrombocytopoiesis and decreased erythropoiesis. These findings support the hypothesis of competition between precursor cells of the erythrocytic and megakaryocytic cell lines (stem-cell competition) as the cause of thrombocytopenia in EPO-treated mice and the cause of anemia in mice whose platelet production rates were increased.